FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

Ketamine has long been seen as a potential ... who have cycled through multiple treatments without relief. Spravato (esketamine) has been touted as a potential blockbuster for Janssen, which ...

In 2019, the FDA approved a ketamine-related chemical developed by Johnson & Johnson for severe depression. The drug, Spravato, is subject to strict FDA safety rules on where and how it can be ...

Ketamine can trigger symptoms similar to those of schizophrenia, but it isn’t known to cause the disorder itself. Ketamine is gaining attention for its potential to treat depression and other ...

Esketamine, an anaesthetic derived from Ketamine, was approved for use in treating patients with Major Depressive Disorder (MDD) by the Health Sciences Authority (HSA) back in Oct. 2020.

A researcher is working on apps that he hopes will be able to identify signs of depression. The programs take and analyze photos of the eyes and face while someone uses the smartphone for other ...